RxDoctor Payments Data

Rebecca Rivardo, PA

Physician Assistant · Honesdale, PANPI 1326237710

Payments from drug & device makers

$1,572in general payments, 2019–2025

Across 93 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$430
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$341
  • Madrigal Pharmaceuticals$180
  • Johnson & Johnson$157
  • Lilly USA, LLC$94
  • Novo Nordisk$66
  • plus $305 from 9 others

What the payments were for

  • Food & beverage$1,572100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,572 in reported general payments places this provider in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$21,624
Medicare patients
162
Services billed
162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf)Adalimumab13$87,254
LinzessLinaclotide47$56,053
ZenpepLipase/Protease/Amylase16$34,306
Mesalamine36$22,988
CreonLipase/Protease/Amylase16$19,996
Pantoprazole Sodium548$9,332
Dexlansoprazole DrDexlansoprazole27$8,128
Omeprazole437$7,270
Mesalamine ErMesalamine13$5,311
Famotidine256$3,893
Sucralfate84$3,081
CholestyramineCholestyramine (With Sugar)24$2,228
Ursodiol13$2,185
Esomeprazole Magnesium59$2,059
Balsalazide Disodium12$1,485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Linzess, Creon$430$163,30376 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Honesdale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →